Becton Dickinson UK Ltd is recalling multiple batches of ChloraPrep antiseptic applicators due to potential sterility compromise in the packaging process, according to the UK Medicines and Healthcare products Regulatory Agency (MHRA). The Class 2 medicines recall affects both ChloraPrep 2% 1mL and ChloraPrep Frepp 2% 1.5mL applicators used for pre-surgical skin preparation.
Key takeaways
- Multiple batches of ChloraPrep applicators recalled due to packaging sterility breach
- Affects both 1mL and 1.5mL formulations used in surgical settings
- Healthcare facilities advised to quarantine affected stock immediately
ChloraPrep Products Under Recall
Two antiseptic formulations affected by sterility concerns, 2024
Source: MHRA, 2024 | Georgian Medical Journal News
Sterility Breach in Packaging Process
The recall notice, designated EL(26)A/26, identifies a potential breach of sterility during the packaging process that could compromise product integrity. Becton Dickinson UK Ltd initiated the voluntary recall as a precautionary measure following identification of the manufacturing issue.
ChloraPrep products contain 2% chlorhexidine gluconate and are widely used in healthcare settings for surgical site preparation. The FDA’s experience with similar recalls demonstrates the critical importance of maintaining sterility in topical antiseptic products used in invasive procedures.
Clinical Impact and Risk Assessment
The potential sterility compromise poses infection risks when contaminated applicators are used for pre-surgical skin preparation. Healthcare facilities must immediately quarantine all affected batches and conduct inventory checks to identify recalled products in their supply chain.
The Centers for Disease Control and Prevention emphasizes that proper antiseptic application is crucial for preventing surgical site infections, making product sterility a fundamental safety requirement. Healthcare providers should review their quality and safety protocols to ensure rapid response to such recalls.
Class 2 medicines recall indicates potential patient safety risk requiring immediate action by healthcare providers to quarantine affected stock
— MHRA Drug Safety Alert (EL(26)A/26, 2024)
What this means
Frequently asked questions
What should healthcare facilities do with recalled ChloraPrep products?
Immediately quarantine all affected batches, conduct inventory checks, and contact Becton Dickinson for return instructions. Do not use any recalled products.
How can sterility compromise affect patient safety?
Non-sterile antiseptic applicators could introduce pathogens during surgical site preparation, potentially leading to surgical site infections or other complications.
Are there alternative antiseptic products available?
Healthcare providers should consult their pharmacy departments for approved alternative chlorhexidine preparations or other antiseptic solutions for surgical preparation.
This recall underscores the importance of robust manufacturing quality systems for sterile medical products. Healthcare facilities should strengthen their supply chain monitoring and establish clear protocols for rapid response to product safety alerts to minimize patient exposure risks.
Was this article helpful?
Related Coverage
